Clinical Trial

A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates

Study acronym: REAL-HTN
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Protocol Amendment History 4 changes
notable Primary completion pushed: 2027-06-01 -> 2027-08-02 2026-07-23
minor Completion pushed: 2027-06-01 -> 2027-08-02 2026-07-23
notable Primary completion pushed: 2027-04-18 -> 2027-06-01 2026-05-23
minor Completion pushed: 2027-04-18 -> 2027-06-01 2026-05-23
Trial Details
NCT Number NCT07465666
Lead Sponsor Novartis Pharmaceuticals
Conditions Hypertension
Enrollment 500 participants
Start Date 2026-08-01
Primary Completion 2027-08-02 (estimated)
Study Completion 2027-08-02 (estimated)
Updated on ClinicalTrials.gov 2026-07-22